Baidu
map

Expert Re Clin Phar :“放弃”他汀类药物有了新证据

2018-09-28 王菲 中国科学报

近日,来自美国、爱尔兰、意大利、瑞典、法国和日本等国的17位医生发表的一篇综述文章称,胆固醇或“坏”胆固醇水平高与心脏病无关,并要求医生“放弃”使用他汀类药物。

近日,来自美国、爱尔兰、意大利、瑞典、法国和日本等国的17位医生发表的一篇综述文章称,胆固醇或“坏”胆固醇水平高与心脏病无关,并要求医生“放弃”使用他汀类药物。

一直以来,高水平的低密度脂蛋白胆固醇(LDL-C)被认为是引发心脏病的主要原因,心脏病最主要的“杀手”之一。

然而,一项基于大约130万患者数据的新研究表明,将他汀类药物作为治疗心脏病的主要方式具有“可疑的益处”。该论文于前不久发表在《临床药理学专家评论》期刊上。

文章对他汀类药物的一些综述评论提出异议,作者们认为这些评论是“基于误导性的统计数据,因为这些数据去掉了失败的试验并忽略了许多相互矛盾的观察”。他们还得出结论,他汀类药物治疗有许多严重的副作用,并称这些已被某些试验“最小化”。

该文章作者包括爱尔兰戈尔韦市的国际血管外科学会教授Sherif Sultan,The Great Cholesterol Con一书的作者Malcolm Kendrick博士,以及美国神经科学家和血管疾病研究员David M Diamond博士。

其中,作者Sherif Sultan教授介绍,尽管有未经证实的益处和严重的副作用,目前世界各地有数百万人正在服用他汀类药物,包括许多没有心脏病史的人。

“我们建议临床医生放弃使用他汀类药物和PCSK-9抑制剂,而是针对心血管疾病的致病原因进行判断和治疗。”Sultan说。PCSK-9抑制剂是一类相对较新的降胆固醇治疗方法,目前这种抑制剂正在广泛推广,成本每年约为2万欧元。

关于降胆固醇治疗是否能降低患心血管疾病的风险问题,该文章称,2005年欧洲和美国卫生部门提出的新法规规定,允许所有的试验数据公开。而文章研究显示,在2000年至2012年期间,在12个欧洲国家使用他汀类药物与降低死亡率无关。

而且,专家们发现,在一般人群中,高“坏”胆固醇水平似乎与患心血管病风险无关,即使是家族性高胆固醇血症(一种以高LDL-C水平为特征的遗传性疾病)的个体,与其患病风险也均无关。

作者表示,使用降胆固醇药物的好处值得怀疑。他们发现,高总胆固醇与动脉粥样硬化(动脉硬化)无关,并且有4项研究证实LDL-C与动脉粥样硬化之间缺乏关联。

同时,他们发现急性心肌梗死患者的胆固醇水平低于正常水平,而“坏”胆固醇水平低的健康人群患传染病和癌症的风险显著增加。

Sultan还介绍了一项最惊人的发现,LDL-C高的老年人更长寿。

而对于已经患有心脏病高风险的患者,专家们同意,特别是那些已有过心脏病发作或中风的患者,他汀类药物被证明是“救生员”,可以减少再次发作的机会。

不过,需要提醒的是,对于已服用他汀类药物的患者应继续服用。如果患者有任何疑虑,请向专业医生咨询。

原始出处:

Uffe Ravnskov, Michel de Lorgeril, David M Diamond, et.al. LDL-C Does Not Cause Cardiovascular Disease: a comprehensive review of current literature. Expert Review of Clinical Pharmacology 31 Aug 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044524, encodeId=eaf8204452431, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Fri Nov 02 19:02:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727626, encodeId=417e1e276269f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jul 30 00:02:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350626, encodeId=7ec03506261e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Oct 27 06:38:55 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348759, encodeId=c85c348e595c, content=学习了,谢谢作者分享/, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Oct 10 11:08:32 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347179, encodeId=dfb934e179bf, content=有意思的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93342442178, createdName=123d926dm06暂无昵称, createdTime=Sat Sep 29 07:06:41 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044524, encodeId=eaf8204452431, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Fri Nov 02 19:02:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727626, encodeId=417e1e276269f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jul 30 00:02:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350626, encodeId=7ec03506261e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Oct 27 06:38:55 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348759, encodeId=c85c348e595c, content=学习了,谢谢作者分享/, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Oct 10 11:08:32 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347179, encodeId=dfb934e179bf, content=有意思的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93342442178, createdName=123d926dm06暂无昵称, createdTime=Sat Sep 29 07:06:41 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2019-07-30 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044524, encodeId=eaf8204452431, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Fri Nov 02 19:02:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727626, encodeId=417e1e276269f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jul 30 00:02:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350626, encodeId=7ec03506261e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Oct 27 06:38:55 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348759, encodeId=c85c348e595c, content=学习了,谢谢作者分享/, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Oct 10 11:08:32 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347179, encodeId=dfb934e179bf, content=有意思的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93342442178, createdName=123d926dm06暂无昵称, createdTime=Sat Sep 29 07:06:41 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2018-10-27 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2044524, encodeId=eaf8204452431, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Fri Nov 02 19:02:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727626, encodeId=417e1e276269f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jul 30 00:02:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350626, encodeId=7ec03506261e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Oct 27 06:38:55 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348759, encodeId=c85c348e595c, content=学习了,谢谢作者分享/, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Oct 10 11:08:32 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347179, encodeId=dfb934e179bf, content=有意思的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93342442178, createdName=123d926dm06暂无昵称, createdTime=Sat Sep 29 07:06:41 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2018-10-10 1e145228m78(暂无匿称)

    学习了,谢谢作者分享/

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2044524, encodeId=eaf8204452431, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Fri Nov 02 19:02:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727626, encodeId=417e1e276269f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jul 30 00:02:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350626, encodeId=7ec03506261e, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Oct 27 06:38:55 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348759, encodeId=c85c348e595c, content=学习了,谢谢作者分享/, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Oct 10 11:08:32 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347179, encodeId=dfb934e179bf, content=有意思的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93342442178, createdName=123d926dm06暂无昵称, createdTime=Sat Sep 29 07:06:41 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2018-09-29 123d926dm06暂无昵称

    有意思的研究

    0

相关资讯

他汀+阿司匹林,一对儿好搭档

他汀稳定斑块,不让易损斑块发生破裂;阿司匹林抑制血小板,使得血液变稀,一旦发生了斑块破裂,不容易形成血栓,或者血栓形成得少了,两者协同作用,防止发生血栓性的血管事件,如心肌梗死、脑梗死和血管性死亡。

Eur Heart J:长期应用他汀 有无必要担心不良反应

他汀是临床上应用非常普遍的一类降脂药物,目前大量文献资料均证实和肯定了他汀的降脂疗效和心血管获益。但任何药物都是“双刃剑”,有治疗效果就有不良反应,他汀也不能幸免。长期服用他汀有哪些不良反应呢?这些不良反应是否会抵消其心脑血管获益?我们又该如何看待和理解他汀的心脑血管获益与不良反应呢?

冠脉钙化评分或可在一定程度上决定是否使用他汀

在7月27日~29日举行的美国预防心脏病学会2018年会中公布的一项报告表明,使用冠状动脉钙化(CAC)评分有助于更好的决定是否进行他汀治疗。

Clin Infect Dis:他汀增加流感疫苗接种者流感风险?想多了

2018年7月,美国和西班牙学者在《Clin Infect Dis》发表一项研究,考察了他汀使用与2010~2015年接种标准剂量或高剂量流感疫苗的使用Medicare医疗保险的老年人流感相关结局的风险之间的相关性。

Neurology:他汀具有预防脑出血的作用?

心血管病危险因素会增加缺血性卒中和脑出血(ICH)的风险。HMG-CO还原酶抑制剂(他汀)是一种降脂药物,广泛应用于血管病的一级和二级预防之中。然而,人们关注他汀是否会增加ICH的风险。

Clin Gastroenterol H:平时服用他汀 凶残的胰腺癌来临时能有一线生机?

胰腺癌被称为“癌中之王”,并不是浪得虚名,死亡率高达99%。美国作家埃德加·斯诺、《人鬼情未了》的男主角帕特里克、歌王帕瓦罗蒂、原国务院副总理黄菊、九段棋手陈祖德等,这些大家所熟知的大人物,尽管声名显赫,也拥有优越的医疗条件,最后也都还是没能从胰腺癌的魔爪下觅得生机。

Baidu
map
Baidu
map
Baidu
map